#Tuberculosis #MDRTB #OralTreatment #Bedaquiline #Efficacy #Safety
Multidrug-resistant tuberculosis (MDR-TB) is a
particularly concerning form of TB, defined by
resistance to isoniazid and
rifampicin—the two cornerstone drugs in standard TB treatment. It causes
hundreds of thousands of cases worldwide each year and poses a
growing threat
to public health, especially in high-burden or resource-limited countries.
Standard treatments for MDR-TB are
long,
complex, and often poorly
tolerated. They typically last
18 to 24 months,
involve multiple medications, and frequently include
prolonged use of
injectable drugs, which are associated with
severe side effects. Despite these
efforts,
treatment success rates remain low—around
60%—and adherence is often
compromised due to the treatment burden.
To address this challenge, the
World Health
Organization (WHO) updated its guidelines in 2020, recommending
all-oral
regimens lasting 9 to 11 months without injectables for patients whose TB
strain is not resistant to fluoroquinolones. These new strategies aim to
improve treatment acceptability, safety, and efficacy while
reducing duration
and toxicity.
This study explores the efficacy and safety of
a short, all-oral regimen based on
bedaquiline—a newer, highly bactericidal
drug—combined with other next-generation agents (linezolid, clofazimine,
moxifloxacin, cycloserine). The new regimen is compared with traditional
treatments that include either
toxic injectables or
high-dose isoniazid, in
a
cohort of MDR-TB patients in China—a country where disease burden remains high
and treatment options limited.
Read next: 4 months to change everything?
MDR-TB: has the miracle pill been found?
In this study, 360 patients were enrolled and divided into three groups:
- Group A
(control, injectable):
High-dose isoniazid + amikacin (injectable) + other conventional anti-TB
drugs (duration: 9–11 months)
- Group B
(oral without bedaquiline):
Same regimen as Group A, but with linezolid replacing amikacin
- Group C
(new all-oral regimen):
Bedaquiline + linezolid + clofazimine + moxifloxacin + cycloserine
(intensive phase: 4–6 months), followed by moxifloxacin + clofazimine +
cycloserine (5 months)
Treatment efficacy was assessed by the
treatment success rate (cure or treatment completion).
Sputum culture
conversion and
closure of pulmonary cavities were also evaluated, along with
adverse events.
The findings show that
Group C achieved the
best clinical outcomes. The
success rate (cure or treatment completed) reached
90.3%, compared to
75.0% in Group B and
57.1% in Group A. Additionally,
sputum
culture conversion and cavity closure occurred
more rapidly and more frequently
in Group C, indicating a more effective therapeutic response.
Loss to follow-up
was also
significantly lower in Groups B and C, suggesting better
treatment
adherence with oral regimens.
In terms of
safety, Group C demonstrated an
overall favorable profile, although some side effects were reported.
Hyperuricemia was
less common in Groups B and C than in Group A. However,
QTc
prolongation was observed in
24.3% of patients in Group C, requiring cardiac
monitoring.
Peripheral neuropathy was reported in
25.2% of patients in Group C.
Importantly,
no serious adverse events were reported across the study,
reinforcing the
overall safety of the all-oral regimen.
A future without injections for drug-resistant TB?
Multidrug-resistant tuberculosis (MDR-TB) is a severe and hard-to-treat form of
TB, associated with high morbidity. The main challenge lies in the toxicity of
injectable drugs and the prolonged treatment duration, which hinder both
patient adherence and therapeutic success. These issues highlight the urgent
need for shorter, better-tolerated, and fully oral treatment regimens.
This study aimed to assess the
efficacy and
safety of a 9-month injection-free regimen based on
bedaquiline, compared to
traditional treatments in MDR-TB patients. The results demonstrate that the
all-oral regimen is
more effective, better tolerated, and
more acceptable to
patients—with a
success rate exceeding 90% and
better adherence than
conventional regimens.
Further multicenter, long-term controlled
trials are needed to
validate these findings and support
broader adoption of
this treatment approach, especially in countries where access to bedaquiline
remains limited. If confirmed, this short-course regimen could
revolutionize
MDR-TB management by
shortening treatment duration, reducing side effects, and
improving patient quality of life.
Read next: The burden of tuberculosis in adolescents and young adults
